Avatrombopag not checked
FollowEvery change as it happens, and a Monday email
Trials
3 active
3 in total · 2 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Trial participants will receive avatrombopag as 20 mg film-coated tablets. On-site administration by the trial team is required on (1) Day 1/Visit 2 (first dose) and (2) the first day a participant is titrated to 80 mg once daily (earliest Visit 6).”In the company’s words, NCT07786922 on ClinicalTrials.gov
- Tested for
- Aplastic Anemia
- Main trialPhase 2/3
- “This research study is testing a medicine called avatrombopag in adults with aplastic anemia, a rare condition where the bone marrow does not produce enough blood cells. The study will include about 26 participants from Japan, South Korea, and Taiwan whose disease has not responded to standard treatment, who cannot receive standard treatment, or whose disease has returned after previous treatment. The goal is to learn how well avatrombopag works and how safe it is for these patients.”In the company’s words, NCT07786922 on ClinicalTrials.gov
Other drugs for Aplastic Anemia
Coming up1
- 30 Jun 2028Phase 2/3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2/3Not yet recruiting | 30 Jun 2028 | A Study of Avatrombopag in Adults With Aplastic Anemia Who Did Not Respond to, Cannot Receive, or Had Return of Disease After Standard Treatment | |
| Phase 3Authorised | not given | Comprehensive Evaluation of Two Second-Line Therapeutic Approaches for Immune Thrombocytopenia (ITP) – a Pragmatic Randomized Controlled Trial - Holistic Study | |
| Phase 2Authorised | not given | Complex immunomodulatory therapy for patients with immune thrombocytopenia (T-MEM) |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026